Panacea Biotec, PT Bio Farma enter into measles vaccine agreement

By Elaine Rigoli

Tampa, Fla., July 11 - Panacea Biotec Ltd. and PT Bio Farma have agreed to manufacture and market a measles vaccine.

Panacea said it will supply the vaccine to numerous countries worldwide in furtherance to the current World Health Organization and Unicef Global Measles Reduction Strategy.

Panacea will procure the bulk vaccine from PT Bio Farma and formulate it into a finished product. Panacea will manufacture and supply the measles vaccine in the defined global markets.

The measles vaccine is expected to be commercially ready by the end of 2007.

Measles, an infectious viral disease and cause of infant mortality, is still an epidemic in several parts of the world.

Panacea Biotec is a health-management company based in New Delhi, India.

PT Bio Farma is a vaccine manufacturer and supplier located in Bandung, Indonesia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.